-
-
-
-
-
-
-
Lexaria advances human study testing oral semaglutide formulations
-
-
-
-
-
-
-
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
-
-
-
-
-
-
-
Lexaria in talks with pharma companies for oral GLP-1 drug development
-
-
-
-
-
-
-
Lexaria Bioscience CEO outlines 2025 progress and 2026 plans
-
-
-
-
-
-
-
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
-
-
-
-
-
-
-
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
-
-
-
-
-
-
-
Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH
-
416,936 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

